InvestSMART

Dimerix Limited (ASX: DXB) - Announcements

Current share price for DXB : $0.230 0.005 (2.13%)+

ASX company news and announcements for Dimerix Limited (DXB) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Dimerix Limited (DXB) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Dimerix Limited (DXB), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Dimerix Limited (DXB)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$138 Trading Halt 4 Oct 2023 8:51AM $0.061 $0.230 risen by 277.05%
$138 Notification of Date of 2023 AGM 25 Sep 2023 1:10PM $0.068 $0.230 risen by 238.24%
$138 FDA Approves Qytovra Brand Name 25 Sep 2023 9:23AM $0.062 $0.230 risen by 270.97%
$138 Regulatory Approval received in Malaysia for ACTION3 Study 22 Sep 2023 9:15AM $0.065 $0.230 risen by 253.85%
$138 Application for quotation of securities - DXB 19 Sep 2023 9:40AM $0.070 $0.230 risen by 228.57%
$138 Dimerix Receives $8.9M R&D Tax Incentive Rebate 13 Sep 2023 8:50AM $0.061 $0.230 risen by 277.05%
$138 Appendix 4G and Corporate Governance Statement 30 Aug 2023 9:18AM $0.070 $0.230 risen by 228.57%
$138 Annual Report 30 Aug 2023 9:17AM $0.070 $0.230 risen by 228.57%
$138 Preliminary Final Report 30 Aug 2023 9:15AM $0.070 $0.230 risen by 228.57%
$138 Notification regarding unquoted securities - DXB 28 Aug 2023 9:50AM $0.069 $0.230 risen by 233.33%
$138 Application for quotation of securities - DXB 28 Aug 2023 9:48AM $0.069 $0.230 risen by 233.33%
$138 Notification regarding unquoted securities - DXB 9 Aug 2023 9:27AM $0.070 $0.230 risen by 228.57%
$138 Application for quotation of securities - DXB 9 Aug 2023 9:25AM $0.070 $0.230 risen by 228.57%
$138 Successful Completion of 2nd DSMB Review of FSGS Trial 8 Aug 2023 8:55AM $0.069 $0.230 risen by 233.33%
$138 Investor Presentation 1 Aug 2023 8:54AM $0.072 $0.230 risen by 219.44%
$138 Quarterly Appendix 4C and Activities Report 28 Jul 2023 8:55AM $0.069 $0.230 risen by 233.33%
$138 Dimerix presentation at Bioshares Biotech Summit 24 Jul 2023 12:00PM $0.073 $0.230 risen by 215.07%
$138 DMX-200 FSGS PH3 Kidney Trial Part 1 Outcome set for Q1 CY24 24 Jul 2023 8:32AM $0.072 $0.230 risen by 219.44%
$138 Approval received for Paediatric Investigation Plan from EMA 5 Jul 2023 8:41AM $0.081 $0.230 risen by 183.95%
$138 Change of Director's Interest Notices - NW and SP 4 Jul 2023 1:51PM $0.080 $0.230 risen by 187.50%
$138 Dimerix confirms Phase 3 study design appropriate for China 3 Jul 2023 8:36AM $0.062 $0.230 risen by 270.97%
$138 Application for quotation of securities - DXB 29 Jun 2023 9:01AM $0.060 $0.230 risen by 283.33%
$138 Application for quotation of securities - DXB 29 Jun 2023 9:00AM $0.060 $0.230 risen by 283.33%
$138 Application for quotation of securities - DXB 29 Jun 2023 8:59AM $0.060 $0.230 risen by 283.33%
$138 Application for quotation of securities - DXB 29 Jun 2023 8:59AM $0.060 $0.230 risen by 283.33%

276 - 300 of 739 results

Page 12 of 30

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.